Form 4: Larimar Therapeutics Director Acquires Stock Options

Director Jonathan S. Leff acquired 19,000 stock options in Larimar Therapeutics, Inc. on May 13, 2025.

Summary

• Jonathan S. Leff, a director of Larimar Therapeutics, Inc., acquired 19,000 stock options on May 13, 2025.
• The exercise price of these options is $1.875.
• The options vest on the earlier of May 13, 2026, or the date of the company's next annual meeting of stockholders, contingent upon continued service on the Board of Directors.
• Leff disclaims beneficial ownership of the securities, holding the options for the benefit and at the direction of Deerfield Management Company, L.P.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option acquisition by a director. There's no indication of positive or negative sentiment from the filing itself.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring such filings can provide insights into management's sentiment and expectations regarding the company's future performance.

Key Dates

Keywords

stock options, Larimar Therapeutics, director, Jonathan S. Leff, beneficial ownership, Deerfield Management Company, LRMR